New Cancer Cure Drug Raw Material Medical Ibrutinib powder CAS 936563-96-1

Basic Information
Place of Origin: China
Brand Name: Senwayer Brand
Certification: ISO, 9001, USP
Model Number: 936563-96-1
Minimum Order Quantity: 10grams
Price: Discount is possible if your order is big enough
Packaging Details: 10g, 20g, 50g , 100g, 500g. 1kg, 10kg
Delivery Time: within 2 working days
Payment Terms: T/T in advance, Money Gram, Western Union, Bank Transfer.
Supply Ability: 1000kg/month
Detail Information
CAS: 936563-96-1 Apparence: White Powder
Purity: 99% Other Name: PCI-32765, Ibrutinib
Function: Cancer Cure Drug Stock: Enough Stock
High Light:

anti cancer drugs


antineoplastic drugs

Product Description

Medical Ibrutinib powder CAS 936563-96-1 New Cancer Cure Drug Raw Material Powder


Quick detail

Name: PCI-32765
CAS No.: 936563-96-1
Formula: C25H24N6O2
Molecular Weight: 440.50
Synonyms: PCI-32765;1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)pyrazolo[3, 4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one;
Density: 1.3±0.1 g/cm3
Boiling Point: 715.0±60.0 °C at 760 mmHg
Flash Point: 386.2±32.9 °C
Appearance: White Powder


Ibrutinib Description

The PCI-32765, with the CAS registry number 936563-96-1, is also known as 1-{(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl}-2-propen-1-one. This chemical's molecular formula is C25H24N6O2 and molecular weight is 440.50. What's more, both its IUPAC name and systematic name are the same which is called 1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)pyrazolo[3, 4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one. PCI-32765 is an experimental drug candidate for the treatment of various types of cancer. It also has potential effects against autoimmune arthritis


Ibrutinib Application

Ibrutinib is a kind of Bruton tyrosine kinase (BTK) inhibitor, it could be used for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). MCL and CLL are belonged to the B-cell non-Hodgkin's lymphoma, which is difficult to cure and easy to recurrent. Common chemical immunotherapy does not have the targeting, often occurs 3 or 4 adverse reactions. Ibrutinib and B lymphocytes could target with BTK which is necessary for formation, differentiation, and transmission of information, inhibit BTK activity irreversibly, and inhibit tumor cell proliferation and survival effectively. Ibrutinib could be rapidly absorbed after oral administration, during 1~2h reach maximum blood concentration, adverse reactions belong to one or two, therefore, Ibrutinib will become a new choice of treatment of CLL and MCL.


Ibrutinib Is Used For

  1. Mantle cell lymphoma (MCL) who have received at least one prior therapy.
  2. Chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.
  3. Waldenstrom’s macroglobulinemia

Note: If a drug has been approved for one use, physicians may elect to use this same drug for other problems if they believe it may be helpful.


Ibrutinib Side Effects

1 Ibrutinib side effects are often predictable in terms of their onset, duration, and severity.
2 Ibrutinib side effects are almost always reversible and will go away after therapy is complete.
3 Ibrutinib side effects may be quite manageable. There are many options to minimize or prevent the side effects of ibrutinib.



Metabolism and Elimination

Metabolism and Elimination Ibrutinib primarily metabolized by the cytochrome P450 (CYP3A and a small part of the CYP2D6) and produce a variety of metabolites after metabolism. The metabolite (PCI-45227) is a kind of dihydrodiol substance which is an activity of inhibiting BTK.Compared with Ibrutinib, PCI-45227 has much stronger inhibition on BTK, which is about 15 times stronger. At steady state, the average rate of metabolism of PCI-45227 is around 1~2.8.
Apparent clearance (CL/F) of Ibrutinibis is approximately 1 000 L/h, the half-life (t1/2) is 4~6 h. Ibrutinib mainly be metabolites in the body, excrete with the feces. To healthy subjects by oral radioactive 14C-labeled Ibrutinib, found that nearly 90% of the radiation were eliminated in 168 h, most (about 80%) of them were excreted with the feces, and nearly 10% were excreted in the urine, about 1 % be prototypes were excreted with the feces.
Elimination of Ibrutinib will not make a difference in age (37 to 84 years) and gender, but systemic exposure of patients with moderate hepatic injury will be 6 times higher than in healthy subjects.


New Cancer Cure Drug Raw Material Medical Ibrutinib powder CAS 936563-96-1 0

Contact Details
Abby Xiang

Phone Number : +8617764031156

WhatsApp : +8617764031156